The clinical and in vitro evidence supports the hypothesis that IDH-mutant gliomas exhibit a preferential reliance on BET protein activity, offering a rationale for repurposing BETis to enhance therapeutic strategies for this glioma subtype [101]. This evidence concerns the gene IDH2 and glioma.